Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Fischer

Dermatology Far Rockaway, NY Doctor of Osteopathy

NPI 1538657523 CMS profile 5790478

327 Beach 19Th St, Far Rockaway, NY 11691

Open in the dashboard

General payments

$8,566

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Fischer of Far Rockaway, NY is reported in the CMS Open Payments database as having received $8,566 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,412 61
2024 General $1,798 38
2023 General $1,910 25
2022 General $2,034 35
2021 General $1,168 18
2020 General $229 2
2019 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Fischer
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Daniel Fischer were reported at $1,412. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Daniel Fischer Dermatology median Middle half National median
2019 $16 $454 $129–$1,240 $163
2020 $229 $235 $81–$756 $114
2021 $1,168 $377 $108–$1,108 $132
2022 $2,034 $514 $143–$1,391 $149
2023 $1,910 $607 $159–$1,674 $160
2024 $1,798 $751 $204–$1,903 $164
2025 $1,412 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,322 37 payments
  2. Regeneron Healthcare Solutions, Inc. $1,178 18 payments
  3. Galderma Laboratories, L.P. $748 8 payments
  4. Genzyme Corporation $686 9 payments
  5. Ortho Dermatologics, a division of Bausch Health US, LLC $663 9 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $613 8 payments
  7. Incyte Corporation $570 22 payments
  8. Sun Pharmaceutical Industries Inc. $535 14 payments
  9. E.R. Squibb & Sons, L.L.C. $422 8 payments
  10. Dermavant Sciences, Inc. $395 6 payments
  11. Other $1,435 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,317 177 payments
  2. Education $249 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $972 13 payments
  2. DUPIXENT Inflammation And Immunology $787 10 payments
  3. RINVOQ $771 19 payments
  4. OPZELURA $570 22 payments
  5. VTAMA $425 8 payments
  6. SKYRIZI $422 12 payments
  7. ILUMYA $414 11 payments
  8. TREMFYA $346 4 payments
  9. SOTYKTU $297 5 payments
  10. SILIQ $296 4 payments
  11. Other $3,407 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Dermatology: 534

Drug cost

$122

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Triamcinolone Acetonide Generic 11 $122

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$3,301

Medicare's payments for the services billed

Medicare patients

14

Average age 77

Services billed

42

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 0%
Heart failure 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $262
  • Regeneron Healthcare Solutions, Inc. $203
$466 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $269
$269 — —
RINVOQ
  • AbbVie, Inc. $194
$194 — —
Bimzelx
  • UCB, Inc. $160
$160 — —
VTAMA
  • Dermavant Sciences, Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record